|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/02/24 Ultragenyx Pharmaceutical Inc. 8-K:2,9 5/02/24 9:355K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 8-K Current Report HTML 43K
2: EX-99.1 Miscellaneous Exhibit HTML 175K
4: R1 Document And Entity Information HTML 45K
6: XML IDEA XML File -- Filing Summary XML 11K
9: XML XBRL Instance -- rare-20240502_htm XML 15K
5: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
3: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 70K
Linkbases Document -- rare-20240502
7: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K
8: ZIP XBRL Zipped Folder -- 0000950170-24-052052-xbrl Zip 25K
| 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i May 02, 2024 |
i Ultragenyx Pharmaceutical Inc.
(Exact name of Registrant as Specified in Its Charter)
i Delaware |
i 27-2546083 |
|||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
i 60 Leveroni Court |
|
|||
i Novato, i California |
|
i 94949 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: i 415 i 483-8800 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
i Common Stock, $0.001 par value |
|
i RARE |
|
i Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition. |
On May 2, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
Exhibit No. |
Description |
99.1 |
|
104 |
The cover page from the Company’s Current Report on Form 8-K dated May 2, 2024 formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Ultragenyx Pharmaceutical Inc. |
|
|
|
|
Date: |
By: |
/s/ Howard Horn |
|
|
|
|
Howard Horn |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 5/2/24 | None on these Dates | ||
| 3/31/24 | ||||
| List all Filings | ||||